Primary Immunodeficiency Disorders Market – By Disease Type, By Treatment Type, By Age Group, By End Use – Global Forecast 2025 – 2034

Primary Immunodeficiency Disorders Market Size

The global primary immunodeficiency disorders market was valued at USD 7.8 billion in 2024. The market is expected to grow from USD 8.2 billion in 2025 to USD 13.9 billion in 2034, at a CAGR of 6.1% during the forecast period. The market is driven by the rising cases of primary immunodeficiency globally, coupled with increasing awareness among healthcare professionals and patients.
 

For instance, as per the report published by the National Institute of Health, it is estimated that around 6 million people worldwide are affected by primary immunodeficiencies (PIDs), though the vast majority (70-90%) remain undiagnosed in 2021. Over 400 different PIDs have been identified, each resulting from inherited defects in the immune system.
 

Advancement in diagnostics and treatment such as the introduction of innovative gene therapy and biologics are expanding the available treatment options and improving patient outcomes, thereby contributing to market growth. Also, the increasing research funding for the development of novel treatment options is fueling market growth and offering enhanced management strategies for these complex disorders.
 

The market is further strengthened by increasing training in immunology which leads to earlier and more accurate diagnoses. Supportive networks and advocacy groups are helping patients access care and pushing for policy improvements, thereby contributing to market growth. The widespread availability of advanced diagnostic tools such as flow cytometry and genetic panels is increasing detection rates of primary immunodeficiency. Urbanization, better healthcare access, and growing disposable income, especially in emerging economies such as India, China, Brazil, and South Africa also contribute to increase in diagnostic rates, thereby driving the market growth.
 

Primary immunodeficiency disorders (PIDs) are a group of inherited conditions where the immune system doesn't work properly, making individuals more susceptible to infections and other health problems. These disorders are typically genetic, that means they are passed down from parents to children. The market includes various disease types, with product development focusing on rapid symptom relief, preventing recurrence, and improving patient’s health.
 

Primary Immunodeficiency Disorders Market Trends

• The primary immunodeficiency disorders industry is stimulated by growing awareness for primary immunodeficiency disorders and the availability of effective treatments, high prevalence of disorders, and advancement in diagnostic technologies.
   
• Public health campaigns, educational programs, and digital platforms have significantly enhanced awareness among healthcare professionals, and the public is leading to earlier detection. For instance, organizations such as International Patient Organization for Primary Immunodeficiencies (IPOPI) and national PID associations are pushing for recognition of PIDs as disabilities, improving access to care and funding. This shift in health-seeking behavior has led to increased diagnosis and treatment for PID, thereby contributing to market growth.
   
• Also, continuous research and innovation have led to the development of effective, targeted, and patient-centric treatments. These advancements aim to improve treatment outcomes, reduce recurrence rates, and enhance patient compliance.
   
• The integration of biotechnology and advanced novel drug delivery systems has enabled better absorption, sustained drug release, and minimal side effects.
   
• Furthermore, pharmaceutical companies are investing heavily in R&D to develop advanced immunoglobulin replacement therapy (IVIG/SCIG) that remains the cornerstone of treatment.
   
• Gene therapies and biologics are emerging as promising long-term or curative options along with stem cell transplantation increasingly used for severe cases, especially in pediatric patients.
   
• For instance, in June 2024, Grifols, subsidiary Biotest, recieved its first FDA approval with the intravenous immunoglobulin (Ig) therapeutic, Yimmugo for the treatment of primary immunodeficiency.
   
• Thus, the presence of key players along with increasing demand for early and precise diagnosis enables timely treatment, reducing complications and improving outcomes is expected to spur market growth.
   

Primary Immunodeficiency Disorders Market Analysis

In 2021, the global market was valued at USD 6.7 billion. The following year, it saw a slight increase to USD 7 billion, and by 2023, the market further climbed to USD 7.4 billion.
 

Based on disease type, the global market is divided into antibody deficiencies, combined immunodeficiencies, complement deficiencies, phagocytic disorders and other disease types. The antibody deficiencies segment dominated the market in 2024 and was valued at USD 4.1 billion.
 

• The high prevalence of antibody deficiencies with increasing conditions such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA) drives the growth of the market.
   
• For instance, as per the report published by the Immune Deficiency Foundation, the prevalence of primary antibody deficiencies (PAD) is estimated to be around 1 in 2,000 children and 1 in 1,200 individuals of any age.
   
• Specifically, common variable immunodeficiency (CVID) has a prevalence of about 1 in 25,000. Secondary antibody deficiencies, while less well-defined, are thought to be significantly more common than PAD, potentially 30 times more frequent.
   
• Patients with antibody deficiencies typically require regular immunoglobulin replacement therapy (IVIG or SCIG) to prevent infections. This creates a recurring demand for immunoglobulin products.
   
• Further, the segment growth is supported by improved access to genetic testing, serum immunoglobulin level assays, and flow cytometry that has led to earlier and more accurate diagnosis of antibody deficiencies. Early diagnosis enables timely treatment, reducing complications and improving patient outcomes.
   

Based on the treatment type, the global primary immunodeficiency disorders market is categorized into immunoglobulin replacement therapy (IRT), hematopoietic stem cell transplantation (HSCT), gene therapy and other treatment types. In 2024, the immunoglobulin replacement therapy (IRT) segment accounted for the largest share of 68.3% in the global market.
 

• The immunoglobulin replacement therapy segment dominance was driven by the increasing dependency on lifelong immunoglobulin therapy to prevent infections. This creates a stable and recurring demand for IRT products, especially IVIG (intravenous) and SCIG (subcutaneous) formulations.
   
• Innovations in recombinant immunoglobulin and extended half-life formulations are enhancing treatment efficacy and patient adherence, thereby contributing to market growth.
   
• Also, ongoing clinical developments and the introduction of advanced IRT therapy with improved patient compliance and treatment outcomes contribute to market growth.
   
• The growing awareness among healthcare providers and patients is leading to earlier diagnosis and timely initiation of IRT. Thus, the rise in educational campaigns and advocacy by patient organizations are contributing to higher treatment uptake.
   

Based on the age group, the global primary immunodeficiency disorders market is categorized into pediatric and adult. The pediatric segment held the highest market revenue USD 5.1 billion in 2024.
 

• Most PIDs are genetic disorders that occur in early childhood, making the pediatric population the largest affected group. For instance, disorders such as severe combined immunodeficiency (SCID) and X-linked agammaglobulinemia (XLA) are typically diagnosed in the first few years.
   
• Improved access to newborn screening, genetic testing, and immune function assays have led to earlier and more accurate diagnosis in children. Early detection allows for timely intervention, which is critical for preventing severe infections and complications.
   
• Several countries are implementing national PID registries and rare disease programs that prioritize pediatric care. Thus, the increasing government support for early intervention and financial assistance is improving access to treatment for children, thereby maintaining its leading position in the market.
   

Based on end use, the primary immunodeficiency disorders market is categorized into hospitals, specialty clinics, homecare settings and other end users. The hospitals segment is expected to reach USD 6.7 billion by 2034.
 

• Hospitals are the primary centers for diagnosing PIDs, which often require advanced immunological and genetic testing. They offer access to immunologists, multidisciplinary care, and laboratory infrastructure, making them essential for accurate and early diagnosis.
   
• Immunoglobulin replacement therapy (IRT), especially IVIG, is commonly administered in hospital settings due to the need for monitoring and infusion support.
   
• Hospitals also manage stem cell transplants, gene therapies, and biologics, which require specialized facilities and post-treatment care, thereby contributing to market growth.
   
• As hospitals remain important point of care seeking specialized attention, this segment continues to contribute significantly to the overall revenue of the market.
   

The North America primary immunodeficiency disorders market dominated the global market with a market share of 41.8% in 2024.
 

The U.S. market was valued at USD 2.5 billion and USD 2.6 billion in 2021 and 2022, respectively. The market size reached USD 2.9 billion in 2024, growing from USD 2.8 billion in 2023.
 

• The U.S. has one of the highest awareness levels among healthcare professionals and the public regarding PID. Widespread use of genetic testing, flow cytometry, and immune profiling enables early and accurate diagnosis, especially in pediatric populations.  
   
• Also, the U.S. healthcare system supports specialized immunology clinics, tertiary care hospitals, and homecare services for PID patients. Access to cutting-edge therapies like gene therapy, stem cell transplants, and biologics is more readily available than in many other regions.
   
• The U.S. is a global leader in biotech research, with significant investment in curative therapies for rare diseases like PID. Development of next-generation immunoglobulin products, gene editing tools, and targeted biologics is accelerating market growth.
   
• Moreover, the market growth is driven by favorable government initiatives, increasing prevalence of PID, the presence of key industry players and rising fundings for the development of primary immunodeficiency disorders therapeutics in U.S.
   

Europe primary immunodeficiency disorders market accounted for USD 2 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe has strong access to immunoglobulin replacement therapy (IRT), stem cell transplants, and emerging gene therapies. The region benefits from centralized healthcare systems that facilitate the distribution and reimbursement of high-cost therapies.
   
• European countries, including Germany, France, and the UK, boost advanced healthcare systems with high expenditure on health services. This robust infrastructure facilitates early diagnosis and treatment of PID, thereby propelling the demand for primary immunodeficiency disorders therapeutics.
   
• European governments are increasingly recognizing PIDs as disabling conditions, which qualifies patients for long-term financial and medical support. Initiatives such as the Irish Primary Immunodeficiencies Association (IPIA) supporting people and families affected by a primary immunodeficiency in Ireland. All activities are funded entirely by donations and grants thereby.
   
• Thus, the availability of such associations along with the growing prevalence of disorder is expected to foster market growth.
   

Germany dominates the European primary immunodeficiency disorders market, showcasing strong growth potential.
 

• Germany has a well-established healthcare system with strong awareness among healthcare professionals about rare diseases like PID. The presence of national PID registries and screening programs has improved early detection, especially in pediatric populations.
   
• German hospitals and laboratories are equipped with cutting-edge diagnostic tools, including genetic sequencing, flow cytometry, and immune profiling. These technologies enable precise classification of PID subtypes, which is essential for personalized treatment planning.
   
• Further, Germany is home to several leading immunology research centers and university hospitals that contribute to PID research and innovation. Collaboration between academia, biotech firms, and government agencies is fostering the development of new therapies and diagnostics.
   

The Asia Pacific primary immunodeficiency disorders market is anticipated to grow at the highest CAGR of 6.4% during the analysis timeframe.
 

• This region is emerging as a fast-growing market, driven by high population density, rising awareness of PID, and increasing healthcare access. For instance, awareness of PID is increasing among healthcare professionals and the general public in countries like India, China, Japan, and South Korea. Similarly, educational campaigns and training programs are helping clinicians recognize PID symptoms earlier, leading to higher diagnosis rates, thereby contributing to market growth.
   
• The availability of genetic testing, flow cytometry, and immune profiling is expanding across Asia-Pacific. These tools are becoming more affordable and accessible, especially in urban centers, enabling early and accurate diagnosis, that further contributes to market growth.
   
• Rapid development of healthcare systems in emerging economies is increasing access to specialist care, immunology clinics, and tertiary hospitals. Countries like China and India are investing in rare disease centers and national registries, which support PID management.
   

China primary immunodeficiency disorders market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• Historically underdiagnosed, PID cases in China are now being identified more frequently due to growing awareness among healthcare professionals and public health campaigns. The expansion of medical education and training programs is helping clinicians recognize PID symptoms earlier, especially in children.
   
• The government of China is investing significantly in healthcare modernization, including the development of rare disease centers and tertiary care hospitals. This infrastructure supports specialist immunology services, which are essential for managing complex PID cases.
•  
• China is also expanding its plasma collection and fractionation capacity to meet domestic demand for immunoglobulin products, thereby contributing to market growth.
   

Brazil leads the Latin American primary immunodeficiency disorders market, exhibiting considerable growth during the analysis period.
 

• Brazil is witnessing a rise in awareness among healthcare professionals and the public regarding PID, leading to earlier and more frequent diagnoses. National medical societies and advocacy groups are promoting education and training to help clinicians identify PID symptoms, especially in children, thereby propelling market growth.
   
• Brazil's National Health Surveillance Agency (ANVISA) is further overseeing pharmaceutical innovation, that ensures safety and efficacy of primary immunodeficiency disorders.
   
• Further, the country’s Unified Health System (SUS) is investing in rare disease programs, including PID, to improve access to care. Public hospitals are being equipped with specialist services for immunology and infectious diseases, supporting PID management.
   

Saudi Arabia primary immunodeficiency disorders market to experience substantial growth in the Middle East and Africa market.
 

• Saudi Arabia’s government is investing in advanced diagnostic technologies, including genetic testing, immune function assays, and flow cytometry. These tools are increasingly available in tertiary hospitals and specialized clinics, enabling early and accurate diagnosis.
   
• As per the title ‘General Population Awareness of Primary Immune Deficiency Disease in Children, Saudi Arabia’ published in the National Library of Medicine journal, the overall incidence of combined immunodeficiency (CID) is estimated to be 1 in 75,000 to 100,000 live births. Since most forms of CID are inherited as autosomal recessive traits, the research suggests that the incidence of CID is higher in country compared to Western countries, probably exceeding 1 in 10,000 live births.
   
• The country’s Vision 2030 includes significant investments in healthcare modernization, which supports the development of rare disease centers and immunology units.
   

Primary Immunodeficiency Disorders Market Share

In 2024, the market remains consolidated, with top key players accounting for approximately 50–55% of the global market share. The top 5 players such as Baxter International, CSL Behring, Takeda Pharmaceutical, ADMA Biologics, and F. Hoffmann La Roche account for a significant share of the global market. Leading pharmaceutical and healthcare companies are leveraging a multi-pronged strategic approach including acquisitions, partnerships, R&D investments, and innovative product launches to reinforce their competitive positioning and respond to the rising prevalence of primary immunodeficiency disorders globally. Companies are actively adopting multi-pronged approaches to address the rising demand for novel drug therapeutics to treat primary immunodeficiency disorders.
 

Primary Immunodeficiency Disorders Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

• ADMA Biologics
• Baxter International
• Biotest (Grifol Group)
• Bluebird Bio
• CSL Behring
• F. Hoffmann La Roche
• Leadiant Biosciences
• Medac
• Miltenyi Biotec
• Takeda Pharmaceutical
• Octapharma
• Orchard Therapeutics
   

Many leading players focus on product approval, advancements and collaboration to gain a competitive edge in the market. For instance, X4 Pharmaceuticals recently announced FDA approval of XOLREMDI (mavorixafor) for WHIM syndrome, a rare PID.
 

Grifols' Biotest received FDA approval for Yimmugo, an immunoglobulin for primary immunodeficiencies.
 

These launches typically include details about the drug's mechanism, target patient population, and clinical trial data supporting its efficacy and safety, along with information about the company and its commitment to addressing rare diseases.
 

Primary Immunodeficiency Disorders Industry News:

• In September 2024, GC Biopharma USA announced the launch and distribution of its immunoglobulin (IG) product ALYGLO (immune globulin intravenous, human-stwk), for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency (PI) expanding access to effective primary immunodeficiency disorders therapy.
   
• In August 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This helped the company expand its product range.
   
• In June 2024, Takeda Canada Inc. announce the marketing authorization (NOC) for HyQvia (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a replacement therapy for primary humoral immunodeficiency (PI) and secondary humoral immunodeficiency (SI) in pediatric patients, strengthening its position in the market in Canada.
   
• In June 2020, Seattle Children's Research Institute, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases, marking a significant advancement in the market.
   

The primary immunodeficiency disorders market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Antibody deficiencies
• Combined immunodeficiencies
• Complement deficiencies
• Phagocytic disorders
• Other disease types

Market, By Treatment Type

• Immunoglobulin replacement therapy (IRT)
• Hematopoietic stem cell transplantation (HSCT)
• Gene therapy
• Other treatment types

Market, By Age Group

• Pediatric
• Adult

Market, By End Use

• Hospitals
• Specialty Clinics
• Homecare Settings
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE